Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration

Non-Malignant Disorders

Sutro nets $85.4M; HiFiBiO pens Takeda R&D...

Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which i...

Aug 02, 2018

Delveinsight
Myocardial Infarction...

Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....

Find More
Delveinsight
Acute Ischemic Stroke (AI...

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....

Find More
Delveinsight
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More